Sqz Biotechnologies Co

Company Profile

Sqz Biotechnologies Co had its IPO on 2020-10-30 under the ticker symbol SQZ.

The company operates in the Healthcare sector and Biotechnology & Medical Research industry. Sqz Biotechnologies Co has a staff strength of 53 employees.

Stock update

Shares of Sqz Biotechnologies Co opened at $0.05 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.05 - $0.06, and closed at $0.05.

This is a +8.09% increase from the previous day's closing price.

A total volume of 20,966 shares were traded at the close of the day’s session.

In the last one week, shares of Sqz Biotechnologies Co have slipped by -36.5%.

Sqz Biotechnologies Co's Key Ratios

Sqz Biotechnologies Co has a market cap of $12.83 million, indicating a price to book ratio of 0.4982 and a price to sales ratio of 1.2437.

In the last 12-months Sqz Biotechnologies Co’s revenue was $18.61 million with a gross profit of $-43050000 and an EBITDA of $-71585000. The EBITDA ratio measures Sqz Biotechnologies Co's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Sqz Biotechnologies Co’s operating margin was -392.43% while its return on assets stood at -33.32% with a return of equity of -104.93%.

In Q2, Sqz Biotechnologies Co’s quarterly earnings growth was a positive 0% while revenue growth was a negative 3.3%.

Sqz Biotechnologies Co’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-2.16 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sqz Biotechnologies Co’s profitability.

Sqz Biotechnologies Co stock is trading at a EV to sales ratio of 0.5793 and a EV to EBITDA ratio of -0.1834. Its price to sales ratio in the trailing 12-months stood at 1.2437.

Sqz Biotechnologies Co stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$54.15 million

Total Liabilities

$9.91 million

Operating Cash Flow

$0

Capital Expenditure

$47000

Dividend Payout Ratio

0%

Sqz Biotechnologies Co ended 2024 with $54.15 million in total assets and $0 in total liabilities. Its intangible assets were valued at $54.15 million while shareholder equity stood at $24.54 million.

Sqz Biotechnologies Co ended 2024 with $0 in deferred long-term liabilities, $9.91 million in other current liabilities, 29000.00 in common stock, $-309431000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $24.71 million and cash and short-term investments were $24.71 million. The company’s total short-term debt was $2,659,000 while long-term debt stood at $0.

Sqz Biotechnologies Co’s total current assets stands at $27.69 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.56 million and inventory worth $0.

In 2024, Sqz Biotechnologies Co's operating cash flow was $0 while its capital expenditure stood at $47000.

Comparatively, Sqz Biotechnologies Co paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.05

52-Week High

$3.388

52-Week Low

$0.046

Analyst Target Price

$19

Sqz Biotechnologies Co stock is currently trading at $0.05 per share. It touched a 52-week high of $3.388 and a 52-week low of $3.388. Analysts tracking the stock have a 12-month average target price of $19.

Its 50-day moving average was $0.15 and 200-day moving average was $0.68 The short ratio stood at 27.26 indicating a short percent outstanding of 0%.

Around 312.3% of the company’s stock are held by insiders while 6658.1% are held by institutions.